AstraZeneca may still be in front in the late-stage race to develop a targeted new drug for non-small cell lung cancer, but new data has analysts wondering if its lead over rival Clovis has shortened in the final stretch.
Cloud computing courtesy of IBM has opened up shop in the heart of the Cambridge, MA, biotech hub today, bringing with it some key industry partnerships and a familiar tech manifesto aimed at commanding a big industry audience.
When Gilead laid out the terms for raising $10 billion yesterday, on top of the blockbuster money it earns on HIV and its hepatitis C drugs acquired in its buyout of Pharmasset, the move immediately stirred fresh buzz about what Gilead was going to buy next, and for how much.
Japanese pharma giant Takeda is promising as much as $500 million to a previously under-wraps biotech company with some early-stage drugs that could provide a more tolerable alternative to steroid treatments.
BioGaia has funnelled SEK 35 million ($4 million) into the bank account of its subsidiary Infant Bacterial Therapeutics to tide the unit over while it considers how to finance clinical trials of an orphan drug. The next move could be a separate listing of the subsidiary.
Edmond de Rothschild Investment Partners and OrbiMed have co-led a $21 million (€18.8 million) Series A round in ReViral, a London-based biotech that is edging a drug against respiratory syncytial virus (RSV) toward the clinic.
After 12 months of fraud accusations, legal threats and stock price swings, Clal Biotechnology and Hyperion Therapeutics now have data from the heavily scrutinized Phase III trial of the diabetes drug at the center of their spat. The trial was a flop, Globes reports.
Faron Pharmaceuticals and Shield Therapeutics have joined a small but growing list of biotechs to pick London over New York for their IPO. Both companies are looking to tap investors for money to push candidates through late-phase trials and on to the market.
MorphoSys is set to ratchet up investment in R&D as it seeks to push candidates through late-phase trials and win the approvals that will allow it to evolve into a fully integrated biopharma company. The additional funds will support the startup of 5 new trials over the next 15 months.
Join me on October 12 for our special half-day biotech conference, in partnership with One Nucleus and OBN. There will be plenty of time for networking and I'll be there throughout, taking your questions as we explore new technologies and new money. Drop me a line if you have a query.
Gene therapy biotech AveXis raised $65 million in Series D cash to advance a potential one-time treatment for the rare spinal muscular atrophy, a debilitating disease with no approved therapies.
Days after the FDA reiterated its demand for a new trial of AcelRx's pain drug Zalviso before it can reconsider a marketing application, the small biotech says it has garnered positive data from its late-stage study of another pain remedy in the pipeline.
Akebia Therapeutics' in-development pill for anemia met its goals in a Phase II study, sending the company's share price soaring as it plots a late-stage trial.
After suffering back-to-back R&D and franchise setbacks, Biogen is beefing up its pipeline with a late-stage autoimmune drug, handing over $60 million in cash and promising up to $484 million in milestones to complete the pact with Mitsubishi Tanabe.
Agenus is trading away future royalties on a GlaxoSmithKline-partnered vaccine adjuvant in exchange for up to $115 million, planning to invest the proceeds in its growing pipeline of immuno-oncology treatments.
GlaxoSmithKline, which recruited more than 16,000 patients in a monumental postapproval effort to distinguish Breo Ellipta by improving the mortality rates of high-risk patients with COPD, says that study failed.
Shares of Tetraphase Pharmaceuticals just got blasted in the wake of a failed Phase III study of its lead antibiotic.
Shares of Flexion Therapeutics cratered Tuesday evening after the Burlington, MA-based biotech said its lead pain treatment flopped in a pivotal Phase IIb study.
Bristol Myers-Squibb, a leader among companies at work in immuno-oncology, is pressing for wider use of its lead treatment with new data showing the injected drug could succeed as part of a first-line treatment in lung cancer.
Partners Merck and Samsung Bioepis recorded their first approval in a sweeping biosimilars alliance, winning a South Korean OK for their copy of Amgen's blockbuster Enbrel.